HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Colgate’s Prestige Skin-Care Acquisitions Inspire Interest In Similar Deals

Executive Summary

Colgate-Palmolive plans to “dial up investments” in prestige skin-care brands EltaMD and PCA Skin, which helped drive North American sales up 3% in the first quarter, says CEO Noel Wallace during his first quarterly presentation as CEO.

You may also be interested in...



Colgate Investment In E-Commerce Staff, Online Brands Pays Off: Sales Up 50%

Strategies including enhanced capabilities, more external talent and online-only launches boosted e-commerce business with 50% sales growth in the fourth quarter. Net sales are anticipated to grow 4% to 7% in 2021.

Colgate Doubles Down On Premium Skin Care With $1.7bn Filorga Acquisition

Back in April, CEO Noel Wallace noted Colgate’s interest in further skin-care M&A during his first quarterly presentation at the firm’s helm. The Filorga purchase is significantly bigger than 2018 deals that whet Colgate’s appetite for high-growth, high-margin skin care and represents a gateway to the fast-growing travel retail channel.

Colgate Direct-To-Consumer Sales Piloted With Tooth-Whitener In US

Colgate test markets its first direct-to-consumer retail program with a tooth-whitening product available by subscription sales, says incoming CEO Noel Wallace. Program not expected to be “huge-scale opportunity” but to help accelerate innovation and better understand consumers.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel